Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.88 |
| ▸ | LCK | P06239 | 1/20 | 0.88 |
| ▸ | FYN | P06241 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27145924 | 1.00 | — | — | |
| Acetic Acid SCHEMBL28097741 | 1.00 | — | — | |
| Acetic Acid SCHEMBL4823161 | 1.00 | — | — | |
| Acetic Acid SCHEMBL3012542 | 1.00 | — | — | |
| Acetic Acid SCHEMBL2224826 | 1.00 | — | — | |
| Acetic Acid SCHEMBL10520351 | 0.94 | — | — | |
| Acetic Acid SCHEMBL6048835 | 0.94 | — | — | |
| Acetic Acid SCHEMBL6291257 | 0.94 | — | — | |
| Acetic Acid SCHEMBL3873115 | 0.94 | — | — | |
| Acetic Acid SCHEMBL912396 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4952661-A | AND DICARBOXYLIC AROMATIC ACID, AND OPTIONALLY A HYDROQUINONE; ANISOTROPIC | MONTEDISON S.P.A. (IT) | 1990-08-28 | — | — | US | claimed |
| EP-0300752-A2 | Thermotropic liquid crystalline polyesters | Montedison S.p.A. (IT) | 1989-01-25 | — | — | EP | claimed |
| JP-5155847-A | — | — | None | — | — | JP | disclosed |
| WO-2024017294-A1 | PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR | 西藏海思科制药有限公司 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023051303-A1 | METAL OXIDE MATERIAL AND PREPARATION METHOD THEREFOR, AND OPTOELECTRONIC DEVICE | TCL科技集团股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
| EP-3853228-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020058844-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-03-26 | — | — | WO | disclosed |
| CN-105481915-A | Preparation method of SGLT-2 inhibitor compound | BEIJING WINSUNNY PHARMACEUTICAL CO LTD | 2016-04-13 | — | — | CN | disclosed |
| US-8501985-B2 | Use of phosphonium salts in coupling reactions and process for their manufacture | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20100197969-A1 | USE OF PHOSPHONIUM SALTS IN COUPLING REACTIONS AND PROCESS FOR THEIR MANUFACTURE | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2010-08-05 | — | — | US | disclosed |
| EP-1856083-A4 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | UNIV MICHIGAN (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2019107-A1 | Use of phosphonium salts in coupling reactions and process for their manufacture | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 2009-01-28 | — | — | EP | disclosed |
| EP-1856083-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006099193-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2003087047-A1 | METAL CHELATE COMPOSITION, MACROMOLECULE COMPLEX THEREOF, PREPARING METHOD THEREOF AND USE | PEPTRON CO., LTD. (KR) | 2003-10-23 | — | — | WO | disclosed |
| JP-2000212742-A | METHOD FOR REPRODUCING METALLIC CVD PRECURSOR | AIR PROD AND CHEM INC | 2000-08-02 | — | — | JP | disclosed |
| CN-1034416-Y | With comfortable kinin antagonists for the preparation method of peptide | He toru spa | 1997-04-02 | — | — | CN | disclosed |
| US-4360527-A | 9-(Hydroxy, lower alkoxy or lower alkanoyloxy)-2-(1H-tetrazol-5-yl)naphtho-(2,1-b)-pyran-1-ones and anti-allergic use thereof | WARNER-LAMBERT COMPANY (US) | 1982-11-23 | — | — | US | disclosed |
| US-4225722-A | Process for the production of 2-(1H-tetrazol-5-yl)-9-hydroxy-1-oxo-1H-naphtho-(2,1-b) pyran and intermediates therefor | WARNER-LAMBERT COMPANY (US) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | BCL2, BAD, BAX | FFAR3 3766/4885LCK 1089/4885FYN 2226/4885 |
| US-20100197969-A1 | USE OF PHOSPHONIUM SALTS IN COUPLING REACTIONS AND PROCESS FOR THEIR MANUFACTURE | PPIP5K2, PHOSPHO1, PNKP | FFAR3 4551/4885LCK 159/4885FYN 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.